We use cookies for a better user experience. Read our Privacy Policy

I Agree

Biological Drugs Market

Biological Drugs Market (Therapeutic Protein - Levemir, Neulasta, Eylea, Rebif, NovoLog, Enbrel, Avonex, Neupogen, Humalog, Victoza, Lantus, Epogen, Aranesp, and Betaseron; Monoclonal Antibody - Avastin, Rituxan, Lucentis, Humira, Herceptin, and Remicade; Vaccine - Gardasil, Prenvar 13, Fluzone, Cervarix, and Varivax) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Global Biological Drugs Market: Snapshot 

The global market for biological drugs has been demonstrating an upward movement since the last few years. The rising concerns over the increasing cases of side-effects caused by conventional medicines and drugs are having a positive impact on the demand for biological drugs across the world. The trend is expected to remain so over the forthcoming years with the opportunity in the worldwide biological drugs market expanding at a CAGR of 10.10% during the period from 2014 to 2020 and reaching US 287.1 bn by the end of the forecast period. 

Demand for Enbrel to Remain Strong in Future 

Lantus, epogen, avonex, victoza, levemir, betaseron, enbrel, humalog, aranesp, neulasta, novolog, neupogen, rebif, and eylea are some of the main therapeutic proteins used in biological drugs. Enbrel has been witnessing a greater demand than other therapeutic proteins, worldwide. Enbrel is used in the treatment of auto-immune diseases, such as juvenile rheumatoid arthritis, plaque, psoriatic, and psoriasis. The growing prevalence of these diseases has influenced the sales of enbrel. 

Analysts expect the segment to rise at a CAGR of 14.50% over the forecast period. However, the concerns over side-effects of this protein, such as multiple sclerosis, tuberculosis, allergic reactions, and blood related infections, may limit its demand to some extent in the years to come. Lantus and neulasta are the other important therapeutic proteins, which are likely to gain impetus in the global market over the next few years. 

Increasing Investments for Research and Development in Biological Drugs to Ensure North America’s Leadership 

The global market for biological drugs is spread across Europe, North America, Asia Pacific, and the Rest of the World. Thanks to the increased application of biological drugs for the treatment of a number of diseases, such as diabetes, cancer, and other chronic medical conditions, North America has emerged as the leading consumer of biological drugs. Over the forthcoming years, investments to increase research and development activities in biological drugs is likely to heighten, which consequently, is expected to boost the North America biological drugs to a great extent. Expanding at a CAGR of 10.90%, this region will continue to hold the leadership in the global market for biological drugs during the forecast period. 

Europe and Asia Pacific are also projected to gain substantial momentum in their respective markets for biological drugs in the coming years, thanks to the growing awareness among consumers pertaining to the efficiency and other benefits of biological drugs. The unmet medical needs in Asia Pacific is also anticipated to add significantly to the growth of the global biological drugs market in the near future. 

GlaxoSmithKline Plc., Biogen Idec, Novartis AG, Baxter International Inc., Amgen Inc., Merck & Co. Inc., Bristol-Myers Squibb Co., Eli Lilly and Co., Pfizer Inc. and Abbott Laboratories are some of the leading manufacturers of biological drugs across the world.

Biological Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

 
Chapter 1 Preface
1.1 Report Description
1.2 Research methodology 
      1.2.1 Sources 
              1.2.1.1 Secondary Research 
              1.2.1.2 Primary Research
              1.2.1.3 Assumptions
 
Chapter 2 Executive Summary 
 
Chapter 3 Global Biological Drugs Market – Industry Analysis 
3.1 Introduction 
3.2 Market Drivers
      3.2.1 Increasing prevalence of chronic diseases enhance the market growth 
      3.2.2 Globally geriatric population increases the demand of biological drugs 
      3.2.3 Various government associations are promoting usage of biological drugs
3.3 Market Opportunities
      3.3.1 Advancement in biomedical science promises to boost the development of new biological products
3.4 Restraints 
      3.4.1 High cost of biological drugs impedes market growth
      3.4.2 Patent expiration of various blockbuster biological drugs
      3.4.3 Risk of adverse effects associated with biological injectable medicines

Chapter 4 Market Trends 
      4.1.1 Increasing use of anti-Vascular Endothelial Growth Factor (VEGF) therapy is gaining popularity in biopharmaceutical industry
      4.1.2 Genetically Modified Organisms (GMOs) are gaining importance in biological drugs market
 
Chapter 5 Porter’s Five Forces Analysis 
      5.1.1 Bargaining power of suppliers 
      5.1.2 Bargaining power of buyers 
      5.1.3 Threat of new entrants 
      5.1.4 Threat of substitutes 
      5.1.5 Degree of competition 
 
Chapter 6 Global Market Size and Forecast 
 
Chapter 7 Segment Analysis, by Therapeutic Protein 
7.1 Enbrel 
7.2 Lantus 
7.3 Neulasta 
7.4 Avonex 
7.5 NovoLog 
7.6 Rebif 
7.7 Humalog 
7.8 Aranesp 
7.9 Epogen
7.10 Levemir 
7.11 Victoza 
7.12 Betaseron
7.13 Neupogen
7.14 Eylea 
 
Chapter 8 Segment Analysis, by mAb 
8.1 Humira 
8.2 Remicade 
8.3 Rituxan 
8.4 Avastin 
8.5 Herceptin 
8.6 Lucentis 
 
Chapter 9 Segment Analysis, by Vaccine 
9.1 Prenvar 13 
9.2 Gardasil
9.3 Fluzone
9.4 Varivax 
9.5 Cervarix 
 
Chapter 10 Regional Analysis
10.1 Scenario in North America
10.2 Scenario in Europe 
10.3 Scenario in Asia 
10.4 Rest of the World (RoW) 
 
Chapter 11 Pipeline Biologic Drugs 
11.1 Biological drugs under development for auto-immune diseases 
11.2 Biological drugs under development for blood diseases 
11.3 Biological drugs under development for cancer and related conditions 
11.4 Biological drugs under development for diabetes and cardiovascular diseases 
 
Chapter 12 Competitive Landscape
 
Chapter 13 Company Profiles 
13.1 Pfizer Inc. 
      13.1.1 Company Overview 
      13.1.2 Product & Segments 
      13.1.3 Financial Performance 
      13.1.4 Strategic Developments 
13.2 Abbott Laboratories
      13.2.1 Company Overview
      13.2.2 Product & Segments 
      13.2.3 Financial Performance 
      13.2.4 Strategic Developments 
13.3 Novartis AG 
      13.3.1 Company Overview 
      13.3.2 Product & Segments 
      13.3.3 Financial Performance 
      13.3.4 Strategic Developments 
13.4 Eli Lilly and Company 
      13.4.1 Company Overview 
      13.4.2 Product & Segments 
      13.4.3 Financial Performance
      13.4.4 Strategic Developments
13.5 GlaxoSmithKline plc.
      13.5.1 Company Overview
      13.5.2 Product & Segments
      13.5.3 Financial Performance 
      13.5.4 Strategic Developments 
13.6 Bristol-Myers Squibb Company 
      13.6.1 Company Overview 
      13.6.2 Product & Segments 
      13.6.3 Financial Performance 
      13.6.4 Strategic Developments 
13.7 Merck & Co., Inc. 
      13.7.1 Company Overview 
      13.7.2 Product & Segments 
      13.7.3 Financial Performance 
      13.7.4 Strategic Developments 
13.8 Amgen Inc. 
      13.8.1 Company Overview 
      13.8.2 Product & Segments 
      13.8.3 Financial Performance 
      13.8.4 Strategic Developments 
13.9 Baxter International Inc. 
      13.9.1 Company Overview 
      13.9.2 Product & Segments 
      13.9.3 Financial Performance 
      13.9.4 Strategic Developments 
13.10 Biogen Idec 
      13.10.1 Company Overview 
      13.10.2 Product & Segments 
      13.10.3 Financial Performance 
      13.10.4 Strategic Developments 
List of Tables
 
TABLE 1 Market Snapshot: Global market for biological drugs (2014 & 2020) 
TABLE 2 Drivers for global biological drugs market: Impact analysis 
TABLE 3 Major biological drugs and their treatment for diseases 
TABLE 4 Restraints for global biological drugs market: Impact analysis 
TABLE 5 Major biological drugs and their adverse effects 21
TABLE 6 Global market for biological drugs, by geography 2009-2013 (USD million)
TABLE 7 Global market for biological drugs, by geography 2014-2020 (USD million)
TABLE 8 Global market for biological drugs , by segment 2009-2013 (USD million)
TABLE 9 Global market for biological drugs, by segment 2014-2020 (USD million) 
TABLE 10 Global market for Enbrel , by geography 2009-2013 (USD million) 
TABLE 11 Global market for Enbrel, by geography 2014-2020 (USD million) 
TABLE 12 Global market for Lantus , by geography 2009-2013 (USD million) 
TABLE 13 Global market for Lantus, by geography 2014-2020 (USD million) 
TABLE 14 Global market for Neulasta , by geography 2009-2013 (USD million) 
TABLE 15 Global market for Neulasta, by geography 2014-2020 (USD million) 
TABLE 16 Global market for Avonex, by geography 2009-2013 (USD million) 
TABLE 17 Global market for Avonex, by geography 2014-2020 (USD million) 
TABLE 18 Global market for NovoLog , by geography 2009-2013 (USD million) 
TABLE 19 Global market for NovoLog, by geography 2014-2020 (USD million) 
TABLE 20 Global market for Rebif, by geography 2009-2013 (USD million) 
TABLE 21 Global market for Rebif, by geography 2014-2020 (USD million) 
TABLE 22 Global market for Humalog, by geography 2009-2013 (USD million)
TABLE 23 Global market for Humalog, by geography 2014-2020 (USD million) 
TABLE 24 Global market for Aranesp, by geography 2009-2013 (USD million) 
TABLE 25 Global market for Aranesp, by geography 2014-2020 (USD million) 
TABLE 26 Global market for Epogen, by geography 2009-2013 (USD million) 
TABLE 27 Global market for Epogen, by geography 2014-2020 (USD million) 
TABLE 28 Global market for Levemir, by geography 2009-2013 (USD million) 
TABLE 29 Global market for Levemir, by geography 2014-2020 (USD million) 
TABLE 30 Global market for Victoza, by geography 2009-2013 (USD million)
TABLE 31 Global market for Victoza, by geography 2014-2020 (USD million) 
TABLE 32 Global market for Betaseron, by geography 2009-2013 (USD million) 
TABLE 33 Global market for Betaseron, by geography 2014-2020 (USD million) 
TABLE 34 Global market for Neupogen, by geography 2009-2013 (USD million)
TABLE 35 Global market for Neupogen, by geography 2014-2020 (USD million) 
TABLE 36 Global market for Eylea, by geography 2009-2013 (USD million) 
TABLE 37 Global market for Eylea, by geography 2014-2020 (USD million) 
TABLE 38 Global market for Humira, by geography 2009-2013 (USD million) 
TABLE 39 Global market for Humira, by geography 2014-2020 (USD million) 
TABLE 40 Global market for Remicade, by geography 2009-2013 (USD million) 
TABLE 41 Global market for Remicade, by geography 2014-2020 (USD million) 
TABLE 42 Global market for Rituxan, by geography 2009-2013 (USD million) 
TABLE 43 Global market for Rituxan, by geography 2014-2020 (USD million) 
TABLE 44 Global market for Avastin, by geography 2009-2013 (USD million) 
TABLE 45 Global market for Avastin, by geography 2014-2020 (USD million) 
TABLE 46 Global market for Herceptin, by geography 2009-2013 (USD million)
TABLE 47 Global market for Herceptin, by geography 2014-2020 (USD million)
TABLE 48 Global market for Lucentis, by geography 2009-2013 (USD million)
TABLE 49 Global market for Lucentis, by geography 2014-2020 (USD million) 
TABLE 50 Global market for Prevnar 13, by geography 2009-2013 (USD million)
TABLE 51 Global market for Prevnar 13, by geography 2014-2020 (USD million) 
TABLE 52 Global market for Gardasil, by geography 2009-2013 (USD million) 
TABLE 53 Global market for Gardasil, by geography 2014-2020 (USD million)
TABLE 54 Global market for Fluzone, by geography 2009-2013 (USD million) 
TABLE 55 Global market for Fluzone, by geography 2014-2020 (USD million) 
TABLE 56 Global market for Varivax, by geography 2009-2013 (USD million) 
TABLE 57 Global market for Varivax, by geography 2014-2020 (USD million) 
TABLE 58 Global market for Cervarix, by geography 2009-2013 (USD million) 
TABLE 59 Global market for Cervarix, by geography 2014-2020 (USD million) 
TABLE 60 The North American market for biological drugs, by country 2009-2013 (USD million) 
TABLE 61 The North American market for biological drugs, by country 2014-2020 (USD million)
TABLE 62 The North American market for biological drugs, by therapeutic protein 2009-2013 (USD million)
TABLE 63 The North American market for biological drugs, by therapeutic protein 2014-2020 (USD million) 
TABLE 64 The North American market for biological drugs, by mAb 2009-2013 (USD million) 
TABLE 65 The North American market for biological drugs, by mAb 2014-2020 (USD million) 
TABLE 66 The North American market for biological drugs, by vaccine 2009-2013 (USD million) 
TABLE 67 The North American market for biological drugs, by vaccine 2014-2020 (USD million) 
TABLE 68 The European market for biological drugs, by country 2009-2013 (USD million) 
TABLE 69 The European market for biological drugs, by country 2014-2020 (USD million) 
TABLE 70 The European market for biological drugs, by therapeutic protein 2009-2013 (USD million)
TABLE 71 The European market for biological drugs, by therapeutic protein 2014-2020 (USD million) 
TABLE 72 The European market for biological drugs, by mAb 2009-2013 (USD million) 
TABLE 73 The European market for biological drugs, by mAb 2014-2020 (USD million) 
TABLE 74 The European market for biological drugs, by vaccine 2009-2013 (USD million) 
TABLE 75 The European market for biological drugs, by vaccine 2014-2020 (USD million) 
TABLE 76 The Asian market for biological drugs, by country 2009-2013 (USD million) 
TABLE 77 The Asian market for biological drugs, by country 2014-2020 (USD million)
TABLE 78 The Asian market for biological drugs, by therapeutic protein 2009-2013 (USD million)
TABLE 79 The Asian market for biological drugs, by therapeutic protein 2014-2020 (USD million)
TABLE 80 The Asian market for biological drugs, by mAb 2009-2013 (USD million) 101
TABLE 81 The Asian market for biological drugs, by mAb 2014-2020 (USD million) 102
TABLE 82 The Asian market for biological drugs, by vaccine 2009-2013 (USD million) 
TABLE 83 The Asian market for biological drugs, by vaccine 2014-2020 (USD million) 
TABLE 84 Some pipeline biological drugs for auto-immune diseases 
TABLE 85 Some pipeline biological drugs for blood diseases
TABLE 86 Some pipeline biological drugs for cancer and related conditions 
TABLE 87 Some pipeline biological drugs for diabetes and cardiovascular diseases
TABLE 88 Pfizer major product segments 
TABLE 89 Abbott major product categories 
TABLE 90 Novartis product segments 
TABLE 91 Lilly product segments 
TABLE 92 GlaxoSmithKline product segments
TABLE 93 Bristol-Myers Squibb key product and brands 
TABLE 94 Merck key product categories 
TABLE 95 Amgen product category 
TABLE 96 Baxter major product categories 
TABLE 97 Biogen Idec major therapies and their uses 

List of Figures 

 

FIG. 1 Biological Drugs Market, by therapeutic proteins, mAbs and vaccine

FIG. 2 Geriatric population in major countries, % in older ages (2000-2050) 

FIG. 3 Biological Drugs Market: Porter’s five force analysis

FIG. 4 Global market for biological drugs, by geography 2013 (% share) 

FIG. 5 Global market for biological drugs, by segment 2013 (% share) 

FIG. 6 Global market for Enbrel, by geography 2013 (% share) 

FIG. 7 Global market for Lantus, by geography 2013 (% share) 

FIG. 8 Global market for Neulasta, by geography 2013 (% share) 

FIG. 9 Global market for Avonex, by geography 2013 (% share) 

FIG. 10 Global market for NovoLog, by geography 2013 (% share) 

FIG. 11 Global market for Rebif, by geography 2013 (% share) 

FIG. 12 Global market for Humalog, by geography 2013 (% share) 

FIG. 13 Global market for Aranesp, by geography 2013 (% share) 

FIG. 14 Global market for Epogen, by geography 2013 (% share) 

FIG. 15 Global market for Levemir, by geography 2013 (% share) 

FIG. 16 Global market for Victoza, by geography 2013 (% share) 

FIG. 17 Global market for Betaseron, by geography 2013 (% share)

FIG. 18 Global market for Neupogen, by geography 2013 (% share) 

FIG. 19 Global market for Eylea, by geography 2013 (% share) 

FIG. 20 Global market for Humira by geography 2013 (% share) 

FIG. 21 Global market for Remicade, by geography 2013 (% share) 

FIG. 22 Global market for Rituxan, by geography 2013 (% share) 

FIG. 23 Global market for Avastin, by geography 2013 (% share)

FIG. 24 Global market for Herceptin, by geography 2013 (% share)

FIG. 25 Global market for Lucentis, by geography 2013 (% share) 

FIG. 26 Global market for Prevnar 13, by geography 2013 (% share) 

FIG. 27 Global market for Gardasil, by geography 2013 (% share) 

FIG. 28 Global market for Fluzone, by geography 2013 (% share) 

FIG. 29 Global market for Varivax, by geography 2013 (% share) 

FIG. 30 Global market for Cervarix, by geography 2013 (% share)

FIG. 31 The North American market for biological drugs, by country 2013 (% share) 

FIG. 32 The North American market for biological drugs, by therapeutic protein 2013 (% share) 

FIG. 33 The North American market for biological drugs, by mAb 2013 (% share) 

FIG. 34 The North American market for biological drugs, by vaccine 2013 (% share)

FIG. 35 The European market for biological drugs, by country 2013 (% share)

FIG. 36 The European market for biological drugs, by therapeutic protein 2013 (% share) 

FIG. 37 The European market for biological drugs, by mAb 2013 (% share) 

FIG. 38 The European market for biological drugs, by vaccine 2013 (% share)

FIG. 39 The Asian market for biological drugs, by country 2013 (% share) 

FIG. 40 The Asian market for biological drugs, by therapeutic protein 2013 (% share) 

FIG. 41 The Asian market for biological drugs, by mAb 2013 (% share) 

FIG. 42 The Asian market for biological drugs, by vaccine 2013 (% share) 

FIG. 43 Competitive landscape of biological drugs market 

FIG. 44 Pfizer revenue and net income 2011-2013 (USD million) 

FIG. 45 Abbott net sales and net earnings 2011-2013 (USD million) 

FIG. 46 Novartis net sales and net income 2011-2013 (USD million) 

FIG. 47 Lilly revenue and net income 2011-2013 (USD million)

FIG. 48 GlaxoSmithKline turnover and profit 2011-2013 (USD million) 

FIG. 49 Bristol-Myers Squibb revenue and net earnings 2011-2013 (USD million) 

FIG. 50 Merck sales and net income 2011-2013 (USD million) 

FIG. 51 Amgen revenue and net income 2011-2013 (USD million) 

FIG. 52 Baxter net sales and net income 2011-2013 (USD million) 

FIG. 53 Biogen Idec revenue and net income 2011-2013 (USD million) 

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

573

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved